Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Mechanisms of Human Cutaneous Microcirculation in Healthy Volunteers

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified March 2007 by University Hospital, Angers.
Recruitment status was:  Recruiting
Sponsor:
Information provided by:
University Hospital, Angers
ClinicalTrials.gov Identifier:
NCT00152724
First received: September 8, 2005
Last updated: March 16, 2007
Last verified: March 2007
  Purpose
Microvascular dysfunctions are critical events in several diseases including diabetes. This study will develop a methodology for microvascular investigation in human skin. The purpose of the study is to investigate the physiological response of the cutaneous microcirculation to physical, thermal, mechanical or chemical stimulations.

Condition Intervention Phase
Healthy Volunteers
Device: pressure strain system, iontophoresis
Drug: scopolamin
Drug: emla
Drug: capsaicin
Drug: aspirin
Drug: clopidogrel
Drug: celecoxib
Drug: indomethacin
Drug: acetylcholine
Drug: sodium nitroprusside
Drug: brethyllium
Device: general and local heating
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Diagnostic
Official Title: Etude de la Reserve Vasomotrice Microcirculatoire cutanée

Further study details as provided by University Hospital, Angers:

Primary Outcome Measures:
  • Amplitude of the vasomotor response to stimuli

Secondary Outcome Measures:
  • Kinetics of the vasomotor response to stimuli

Estimated Enrollment: 85
Study Start Date: January 1996
Estimated Study Completion Date: January 2008
Detailed Description:
This study has investigated various aspects of the physiology of the microcirculation in the past years and is still recruiting under parallel protocols of physiological investigations of the neurovascular control of the cutaneous microcirculation.
  Eligibility

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Healthy volunteers with no clinical signs of, or risk factors for, vascular disease

Exclusion Criteria:

  • Smokers, Pregnancy, Allergy,
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00152724

Locations
France
Laboratoire de Physiologie et Explorations Vasculaires - CHU Angers
Angers, France, 49033
Sponsors and Collaborators
University Hospital, Angers
Investigators
Principal Investigator: Jean Louis SAUMET, MD - PhD University Hospital, Angers
  More Information

Publications:

ClinicalTrials.gov Identifier: NCT00152724     History of Changes
Other Study ID Numbers: CP96-04 
Study First Received: September 8, 2005
Last Updated: March 16, 2007
Health Authority: France: Ministry of Health

Keywords provided by University Hospital, Angers:
Physiology
Microcirculation
Laser-Doppler Flowmetry

Additional relevant MeSH terms:
Clopidogrel
Acetylcholine
Celecoxib
Indomethacin
Capsaicin
Nitroprusside
Platelet Aggregation Inhibitors
Purinergic P2Y Receptor Antagonists
Purinergic P2 Receptor Antagonists
Purinergic Antagonists
Purinergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs
Cyclooxygenase 2 Inhibitors
Cyclooxygenase Inhibitors
Enzyme Inhibitors
Anti-Inflammatory Agents, Non-Steroidal
Analgesics, Non-Narcotic
Analgesics
Sensory System Agents
Peripheral Nervous System Agents
Anti-Inflammatory Agents
Antirheumatic Agents
Gout Suppressants
Tocolytic Agents
Reproductive Control Agents
Antipruritics
Dermatologic Agents
Vasodilator Agents

ClinicalTrials.gov processed this record on December 08, 2016